LEWIS JOEL buys 9,175 shares of GALECTIN THERAPEUTICS INC [GALT]
Transaction increases the holding of LEWIS JOEL in the company to 839,614
By USInMinutes
Published - Apr 03, 2023, 08:36 AM ET
Last Updated - Jul 18, 2023, 04:05 PM EDT
Lewis Joel has bought 9,175 shares of Galectin Therapeutics Inc [GALT] at $2.10 a share.
Galectin Therapeutics Inc [GALT] disclosed in an SEC Form 4 submission Friday, March 31, 2023 that the deal increased Lewis Joel's holding in the company to 839,614.
Galectin Therapeutics Inc [GALT] is a Pharmaceutical Preparations company based in Nevada.
Also Read:
- Galectin Therapeutics Reports the Positive Outcome of the Third Data and Safety Monitoring ...
- Galectin Therapeutics Provides Final Randomization Status of NAVIGATE, its Seamless, Adaptive ...
- Galectin Therapeutics Provides Final Randomization Status of NAVIGATE, its Seamless, Adaptive ...
- Galectin Therapeutics contribution to improve histology interpretation of cirrhotic liver ...
- Galectin Therapeutics to Present at 6th Obesity & NASH Drug Development Summit
NewsInMinutes is an offering of 10kInfo, Inc., bringing you news on the latest regulatory filings. You may subscribe to news alerts here.
Although all care is taken to ensure the accuracy of the data, the article does not intend to replace user diligence while taking decisions of financial or legal implications.